The DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
Open accessAbstract
In its 33 years, ADDR has published regularly on the po5tential of oral delivery of biologics especially peptides and proteins. In the intervening period, analysis of the preclinical and clinical trial failures of many purported platform technologies has led to reflection on the true status of the field and reigning in of expectations. Oral formulations of semaglutide, octreotide, and salmon calcitonin have completed Phase III trials, with oral semaglutide being approved by the FDA in 2019. The progress made with oral peptide formulations based on traditional permeation enhancers is against a background of low and variable oral bioavailability values of ~1%, leading to a current perception that only potent peptides with a viable cost of synthesis can be realistically considered. Desirable features of candidates should include a large therapeutic index, some stability in the GI tract, a long elimination half-life, and a relatively low clearance rate. Administration in nanoparticle formats have largely disappointed, with few prototypes reaching clinical trials: insufficient particle loading, lack of controlled release, low epithelial particle uptake, and lack of scalable synthesis being the main reasons for discontinuation. Disruptive technologies based on engineered devices promise improvements, but scale-up and toxicology aspects are issues to address. In parallel, medicinal chemists are synthesizing stable hydrophobic macrocyclic candidate peptides of lower molecular weight and with potential for greater oral bioavailability than linear peptides, but perhaps without the same requirement for elaborate drug delivery systems. In summary, while there have been advances in understanding the limitations of peptides for oral delivery, low membrane permeability, metabolism, and high clearance rates continue to hamper progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–231 of 231
Sugiyama, T., Yamamoto, A., KAWABE, Y., et al. (1997) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.20.812 · Cited by 28
Dittmann, I., Amasheh, M., Krug, S. M., Markov, A. G., Fromm, M., & Amasheh, S. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1376-5 · Cited by 28
Watari, A., Kodaka, M., Matsuhisa, K., Sakamoto, Y., Hisaie, K., Kawashita, N., Takagi, T., Yamagishi, Y., Suzuki, H., Tsujino, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-15108-y · Cited by 28
Hunt, B., Hansen, B. B., Ericsson, Å., Kallenbach, K., Ali, S. N., Dang‐Tan, T., Malkin, S. J. P., & Valentine, W. J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01125-y · Cited by 28
Drug Delivery Systems in Domestic Animal Species
Brayden, D. J., Oudot, E. J. M., & Baird, A. W. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-10324-7_4 · Cited by 27
Self-citationZhang, L., Shi, Y., Song, Y., Duan, D., Zhang, X., Sun, K., & Li, Y. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1455839 · Cited by 27
Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation
Rao, S. S. C. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818777945 · Cited by 27
Bottom-Up Fabrication of Multilayer Enteric Devices for the Oral Delivery of Peptides
Nemeth, C. L., Lykins, W. R., Tran, H., ElSayed, M. E. H., & Desai, T. A. (2019) · Pharmaceutical Research · doi:10.1007/s11095-019-2618-3 · Cited by 27
Dahlgren, D., Sjöblom, M., Hedeland, M., & Lennernäs, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020099 · Cited by 26
An intestinal paracellular pathway biased toward positively-charged macromolecules
Almansour, K., Taverner, A., Turner, J. R., Eggleston, I. M., & Mrsny, R. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.003 · Cited by 25
Self-citationAlmansour, K., Taverner, A., Eggleston, I. M., & Mrsny, R. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.03.033 · Cited by 24
Self-citationKlonoff, D. C., Bode, B. W., Cohen, N., Penn, M. S., Geho, W. B., & Muchmore, D. B. (2019) · Diabetes Care · doi:10.2337/dc19-0152 · Cited by 24
Binkhathlan, Z., Hamdy, D. A., Brocks, D. R., & Lavasanifar, A. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.03.010 · Cited by 23
Song, Y., Shi, Y., Zhang, L., Hu, H., Zhang, C., Yin, M., Zhang, X., & Sun, K. (2018) · Nanomedicine · doi:10.2217/nnm-2018-0322 · Cited by 23
Garcia-Castillo, M. D., Chinnapen, D. J. ‐., Welscher, Y. M. T., Gonzalez, R. J., Softic, S., Pacheco, M., Mrsny, R. J., Kahn, C. R., von Andrian, U. H., Lau, J. F., et al. (2018) · eLife · doi:10.7554/elife.34469 · Cited by 21
Self-citationMantaj, J., Abu-Shams, T., Enlo‐Scott, Z., Swedrowska, M., & Vllasaliu, D. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01053 · Cited by 21
Defining optimal permeant characteristics for ultrasound-mediated gastrointestinal delivery
Schoellhammer, C. M., Chen, Y., Cleveland, C., Minahan, D. J., Bensel, T., Park, J. Y., Saxton, S. H., Lee, Y. L., Booth, L., Langer, R., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.023 · Cited by 20
(ANS), E. P. O. F. A. A. N. S. A. T. F., Younes, M., Aggett, P. J., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Fernández, M. J. F., Galtier, P., Gott, D. M., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5180 · Cited by 19
Gregory, J. M., Lautz, M., Moore, L. M., Williams, P. E., Reddy, P., & Cherrington, A. D. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13498 · Cited by 19
Ultra-rapid drug delivery in the oral cavity using ultrasound
France, M. M., del Rio, T., Travers, H. I., Raftery, E. M., Xu, K., Langer, R., Traverso, G., Lennerz, J. K., & Schoellhammer, C. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.037 · Cited by 18
Aziz, M., Desai, M., Rawish, F., Viveksandeep, T. C., Albert, E., Jackson, M., & Prateek, S. (2019) · Current Clinical Pharmacology · doi:10.2174/1574884714666190328162637 · Cited by 16
Tuning the PEG surface density of the PEG-PGA enveloped Octaarginine-peptide Nanocomplexes
Samaridou, E., Kalamidas, N., Santalices, I., Crecente‐Campo, J., & Alonso, M. J. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00678-3 · Cited by 14
A new opening for orally taken peptide drugs
Artursson, P., & Lundquist, P. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0513-1 · Cited by 14
Unfair competition governs the interaction of pCPI-17 with myosin phosphatase (PP1-MYPT1)
Filter, J. J., Williams, B. C., Eto, M., Shalloway, D. I., & Goldberg, M. L. (2017) · eLife · doi:10.7554/elife.24665 · Cited by 13
Lohman, R., Nielsen, D. S., Kok, W. M., Hoang, H. N., Hill, T. A., & Fairlie, D. P. (2019) · Chemical Communications · doi:10.1039/c9cc06234c · Cited by 13
Self-citationCatching target receptors for drug and vaccine delivery using TOGA® gene expression profiling
Lo, D. D., Hilbush, B. S., Mah, S. P., Brayden, D. J., Byrne, D., Higgins, L. M., & O’Mahony, D. J. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00091-1 · Cited by 11
Self-citationOverview of Macrocycles in Clinical Development and Clinically Used
Stotani, S., & Giordanetto, F. (2017) · doi:10.1002/9781119092599.ch16 · Cited by 10
Physiology of Calcitonin and Its Therapeutic Uses
Wimalawansa, S. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95758-1 · Cited by 8
Peptide therapeutics for the treatment of gastrointestinal disorders
Fretzen, A. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.11.007 · Cited by 7
Nielsen, D. S., Lohman, R., Hoang, H. N., Fairlie, D. P., & Hill, T. A. (2020) · Australian Journal of Chemistry · doi:10.1071/ch19479 · Cited by 5
Self-citationDiscovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV
Lin, K. W. (2011) · doi:10.1002/9780470929353.ch22 · Cited by 4
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers
Haddadzadegan, S., Dorkoosh, F., & Bernkop-Schnürch, A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114097 · Cited by 424
Advances in Oral Drug Delivery Systems: Challenges and Opportunities
Lou, J., Duan, H., Qin, Q., Teng, Z., Gan, F., Zhou, X., & Zhou, X. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020484 · Cited by 397
Foundations of gastrointestinal-based drug delivery and future developments
Chu, J. N., & Traverso, G. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00539-w · Cited by 289
Metadata
- Authors
- Brayden, D. J., Hill, T. A., Fairlie, D. P., Maher, S., & Mrsny, R. J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 157
- Pages
- 2-36
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3030007836
- Cited by
- 253
- References
- 231
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.